GSK, J&J and AZ top global drug access index, but foundation says plenty more work needs to be done

The article positions the Index as a moment of reckoning for pharmaceutical companies on their performance around access to medicine.

It explains that, while there has been progress, there are still 'gaping holes', particularly in relation to R&D on emerging infectious diseases.

Read the article on the Fierce Pharma website.